|1||NCT00694629||Completed||TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment||
||U.S. Fed / Industry||
||865||All||18 Years and older (Adult, Senior)||NCT00694629||CDC-NCHSTP-5399||December 2008||June 2013||December 2013||June 10, 2008||May 8, 2014||
|2||NCT02563327||Recruiting||Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis||
||U.S. Fed / Other||
||60||All||18 Years and older (Adult, Senior)||NCT02563327||CDC-NCHHSTP-6719||S31PK/PD||May 30, 2016||March 2019||March 2020||September 30, 2015||March 1, 2017||
† Study has passed its completion date and status has not been verified in more than two years.